We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $767M
1-Year Est. Return 119.71%
This Fund
S&P 500
This Quarter Est. Return
+18.13%
1 Year Est. Return
+119.71%
3 Year Est. Return
+244.81%
5 Year Est. Return
+382.5%
10 Year Est. Return
+2,655.81%
AUM
$767M
AUM Growth
+$137M
Cap. Flow
+$31.2M
Cap. Flow %
4.08%
Top 10 Hldgs %
34.48%
Holding
123
New
27
Increased
33
Reduced
30
Closed
18

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$14.4M
2
CYTK icon
Cytokinetics
CYTK
+$12.9M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$12.1M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$10.3M
5
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$7.27M

Top Sells

Rank Stock Value
1
NVMI
Nova
NVMI
+$14.5M
2
TSEM icon
Tower Semiconductor
TSEM
+$8.98M
3
FOLD
Amicus Therapeutics
FOLD
+$8.72M
4
CLBT icon
Cellebrite
CLBT
+$8.7M
5
APLS
Apellis Pharmaceuticals
APLS
+$8.65M

Sector Composition

Rank Sector Weight
1 Healthcare 80.09%
2 Miscellaneous 10.43%
3 Technology 7.55%
4 Utilities 1.93%
5 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TRAW icon
101
Traws Pharma
TRAW
$8.33M
$336K 0.04%
+398,486
New +$549K
EVMN
102
Evommune Inc
EVMN
$436M
$301K 0.04%
22,632
-55,602
-71% -$1.29M
HOWL icon
103
Werewolf Therapeutics
HOWL
$45.9M
$226K 0.03%
626,810
– –
APRE icon
104
Aprea Therapeutics
APRE
$10.2M
$217K 0.03%
270,000
– –
AAOI icon
105
Applied Optoelectronics
AAOI
$8.52B
– –
-73,400
Closed -$6.21M
AMZN icon
106
Amazon
AMZN
$2.79T
– –
-31,940
Closed -$6.65M
APLS
107
DELISTED
Apellis Pharmaceuticals
APLS
– –
-214,914
Closed -$8.65M
ASND icon
108
Ascendis Pharma A/S
ASND
$17.8B
– –
-8,000
Closed -$1.83M
BMY icon
109
Bristol-Myers Squibb
BMY
$139B
– –
-17,500
Closed -$1.06M
CAMT icon
110
Camtek
CAMT
$6.48B
– –
-53,020
Closed -$8.04M
CLBT icon
111
Cellebrite
CLBT
$3B
– –
-631,521
Closed -$8.7M
DTIL icon
112
Precision BioSciences
DTIL
$203M
– –
-40,000
Closed -$220K
ENPH icon
113
Enphase Energy
ENPH
$4.8B
– –
-142,419
Closed -$5.38M
FHTX icon
114
Foghorn Therapeutics
FHTX
$289M
– –
-12,224
Closed -$58.4K
FOLD
115
DELISTED
Amicus Therapeutics
FOLD
– –
-603,377
Closed -$8.72M
IBIT icon
116
iShares Bitcoin Trust
IBIT
$63.4B
– –
-59,505
Closed -$2.29M
NICE icon
117
Nice
NICE
$6.35B
– –
-5,611
Closed -$619K
OLMA icon
118
CALL
Olema Pharmaceuticals
OLMA
$939M
– –
-100,000
Closed -$1.49M
PANW icon
119
Palo Alto Networks
PANW
$271B
– –
-52,800
Closed -$8.46M
SEDG icon
120
SolarEdge
SEDG
$2.08B
– –
-52,836
Closed -$2.7M
SLNO
121
DELISTED
Soleno Therapeutics
SLNO
– –
-216,281
Closed -$7.24M
ZIM icon
122
ZIM Integrated Shipping Services
ZIM
$3.33B
– –
-105,950
Closed -$2.79M
1 2 3 4
5

Similar funds

ISWM
Independent Solutions Wealth Management Williamsville, New York $766M AUM 31.53% 1-Year Est. Return
ACP
Albar Capital Partners London, United Kingdom $767M AUM 61.96% 1-Year Est. Return
NIM
Nexus Investment Management Toronto, Ontario, Canada $767M AUM 30.97% 1-Year Est. Return
ACM
Arvin Capital Management Austin, Texas $766M AUM 36.51% 1-Year Est. Return
CBT
Crews Bank & Trust Wauchula, Florida $766M AUM 19.5% 1-Year Est. Return
SPIA
Strategic Point Investment Advisors Providence, Rhode Island $767M AUM 17.58% 1-Year Est. Return
CNB
Camden National Bank Camden, Maine $767M AUM 14.32% 1-Year Est. Return
HI
Hendershot Investments Centreville, Virginia $766M AUM 10.81% 1-Year Est. Return

Sphera Funds Management's Q2 2026 Portfolio in Review

As of Q2 2026, Sphera Funds Management held 123 positions worth $767M, up 22% from $630M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Sphera Funds Management deployed $31.2M of net new capital in Q2 2026, opening 27 new positions and adding to 33 existing holdings. Its largest new stake was Insmed: 118,800 shares worth $12.7M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 74% a quarter earlier, followed by Miscellaneous and Technology.

On the sell side, the largest reduction was Nova, an estimated $14.5M trimmed.

  • Sphera Funds Management's largest Q2 2026 buy was Insmed: 118,800 shares worth $12.7M.
  • Sphera Funds Management added most to Cytokinetics in Q2 2026, an estimated $12.9M increase.
  • Sphera Funds Management's biggest Q2 2026 reduction was Nova, cutting an estimated $14.5M.
  • Sphera Funds Management fully exited Amicus Therapeutics in Q2 2026, selling an estimated $8.72M.
  • Sphera Funds Management's ten largest holdings make up 34% of its $767M portfolio in Q2 2026.
  • Sphera Funds Management opened 27 new positions and closed 18 in Q2 2026.
  • Sphera Funds Management's portfolio value rose 22% quarter-over-quarter to $767M.

Based on Sphera Funds Management's 13F filing for Q2 2026, filed 14 Aug 2026.